

solo™

The preferred first-line therapy for glaucoma, SLT.


Designed specifically for selective laser trabeculoplasty (SLT), Solo™ allows you to perform quick and highly accurate glaucoma laser treatment customized to each individual patient's response.

LiGHT Trial¹ confirms SLT as preferred first-line therapy for glaucoma

The pivotal results of the multi-center LiGHT trial compared the use of SLT versus drops as a first-line treatment for treatment-naïve patients who had POAG or OHT over 36 months.



SLT (329 patients)
Eye drops (323 patients)



74.2% of SLT patients
reached target IOP, drop-free.



ellex.com

¹ Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Gus Gazzard, Evgenia Konstantakopoulou, David Garway-Heath, et al.; on behalf of the LiGHT Trial Study Group.





Comprehensive energy tracking system,
regulating settings for extended duration

If SLT is ineffective, primary obstruction may reside distal to trabecular meshwork

Eliminate the issues of compliance and side effects associated with medications

Postoperative adjunct to optimize MIGS treatment outcomes

Laser Source	Q-switched, frequency doubled Nd:YAG
Wavelength	Green 532 nm
Energy	0.3 to 2.6 mJ, single pulse, continuously variable
Pulse Width	3 ns
Spot Size	400 μm
Repetition Rate	up to 3 Hz
Aiming Beam	Red 635 nm, adjustable intensity
Magnification	10x, 16x, 28x
Cooling	Air-cooled
Weight	30 kg, 66 lbs (laser only)
Dimensions (HxWxD)	57x75x44 cm, 23x30x18 in (laser only)



Solo™ has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) 510(k) Market clearance for the indication of Selective Laser Trabeculoplasty (Selective Light Therapy, SLT)

